Search
Menu
CASTECH INC - New Building the Bridge of Light

Bayer HealthCare

Facebook X LinkedIn Email
Bayer HealthCare of Berlin has entered into a strategic agreement to transfer its hematological oncology portfolio to Genzyme Corp. of Cambridge, Mass. This includes granting the American company exclusive worldwide licenses for several of the products in the portfolio. In return, the German company will receive milestone payments and royalties, which could add up to as much as $650 million.
Deposition Sciences Inc. - Difficult Coatings - MR-8/23

Published: July 2009
Bayer HealthcareBiophotonicshematological oncologyNews & Features

We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.